Cargando…
Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Second Military Medical University
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875143/ https://www.ncbi.nlm.nih.gov/pubmed/36721690 http://dx.doi.org/10.1016/j.ajur.2022.01.005 |
| _version_ | 1784877897843998720 |
|---|---|
| author | Kurokawa, Masayuki Naito, Sei Kato, Tomoyuki Ushijima, Masaki Yamagishi, Atsushi Sakurai, Toshihiko Nishida, Hayato Tsuchiya, Norihiko |
| author_facet | Kurokawa, Masayuki Naito, Sei Kato, Tomoyuki Ushijima, Masaki Yamagishi, Atsushi Sakurai, Toshihiko Nishida, Hayato Tsuchiya, Norihiko |
| author_sort | Kurokawa, Masayuki |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9875143 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Second Military Medical University |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98751432023-01-30 Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma Kurokawa, Masayuki Naito, Sei Kato, Tomoyuki Ushijima, Masaki Yamagishi, Atsushi Sakurai, Toshihiko Nishida, Hayato Tsuchiya, Norihiko Asian J Urol Letter Second Military Medical University 2023-01 2022-07-16 /pmc/articles/PMC9875143/ /pubmed/36721690 http://dx.doi.org/10.1016/j.ajur.2022.01.005 Text en © 2022 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Letter Kurokawa, Masayuki Naito, Sei Kato, Tomoyuki Ushijima, Masaki Yamagishi, Atsushi Sakurai, Toshihiko Nishida, Hayato Tsuchiya, Norihiko Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma |
| title | Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma |
| title_full | Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma |
| title_fullStr | Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma |
| title_full_unstemmed | Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma |
| title_short | Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma |
| title_sort | complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875143/ https://www.ncbi.nlm.nih.gov/pubmed/36721690 http://dx.doi.org/10.1016/j.ajur.2022.01.005 |
| work_keys_str_mv | AT kurokawamasayuki completeresponsetoanantiprogrammedcelldeath1antibodyfollowingacombinationtherapyofanantiprogrammedcelldeathligand1antibodyandatyrosinekinaseinhibitorformetastaticrenalcellcarcinoma AT naitosei completeresponsetoanantiprogrammedcelldeath1antibodyfollowingacombinationtherapyofanantiprogrammedcelldeathligand1antibodyandatyrosinekinaseinhibitorformetastaticrenalcellcarcinoma AT katotomoyuki completeresponsetoanantiprogrammedcelldeath1antibodyfollowingacombinationtherapyofanantiprogrammedcelldeathligand1antibodyandatyrosinekinaseinhibitorformetastaticrenalcellcarcinoma AT ushijimamasaki completeresponsetoanantiprogrammedcelldeath1antibodyfollowingacombinationtherapyofanantiprogrammedcelldeathligand1antibodyandatyrosinekinaseinhibitorformetastaticrenalcellcarcinoma AT yamagishiatsushi completeresponsetoanantiprogrammedcelldeath1antibodyfollowingacombinationtherapyofanantiprogrammedcelldeathligand1antibodyandatyrosinekinaseinhibitorformetastaticrenalcellcarcinoma AT sakuraitoshihiko completeresponsetoanantiprogrammedcelldeath1antibodyfollowingacombinationtherapyofanantiprogrammedcelldeathligand1antibodyandatyrosinekinaseinhibitorformetastaticrenalcellcarcinoma AT nishidahayato completeresponsetoanantiprogrammedcelldeath1antibodyfollowingacombinationtherapyofanantiprogrammedcelldeathligand1antibodyandatyrosinekinaseinhibitorformetastaticrenalcellcarcinoma AT tsuchiyanorihiko completeresponsetoanantiprogrammedcelldeath1antibodyfollowingacombinationtherapyofanantiprogrammedcelldeathligand1antibodyandatyrosinekinaseinhibitorformetastaticrenalcellcarcinoma |